Statins Inhibit Important Biochemical Pathway - Cause Predictable 'Side Effects'

Categories

Health

Cholesterol lowering statin drugs such as Lipitor, Crestor, Zocor and Pravachol inhibit a liver enzyme which in turn limits the production of mevalonate, blocking an important biochemical pathway in our normal metabolism. Absence or scarcity of mevalonate as induced by statin drugs leads to numerous side effects, some of them very painful, others involving memory and mental and emotional disposition.

But what's a bit of pain, you might ask, to prevent a heart attack? Sometimes we need to suffer in the name of prevention. The doctor has ordered it. You might be surprised to find out that both the muscle pains and the mental fog you feel are not justified by the positive effects of these drugs. The real preventive potential of lowering your cholesterol is greatly in doubt.

'Spacedoc' Duane Graveline, author of Statin Drugs Side Effects: the misguided war on cholesterol

One doctor, Duane Graveline, a former astronaut and now a major critic of the indiscriminate use of statin drugs (see spacedoc.net) has put together the information on the drugs' side effects. He explains the technical details in a way that someone who isn't a doctor can follow without too much trouble.

But even your doctor might learn something new since the pharmaceutical companies are not very forthcoming with this kind of information. So print out this article and pass it on...

- - -

Statin Drugs and the Mevalonate Pathway

(this article is based on writings of Spacedoc Duane Graveline)

When I first started my investigation into the mechanisms of action of the statin drugs, I was still without prejudice towards the drug companies. I candidly assumed both they and I were on the same course – public health good was our goal. Sad to say I was still naïve then and quite unsophisticated as to how the world really works. Is it Voltaire who wrote the novel Candide? Candide was me and I was happy then.

Now, seven years later I am wiser but cynical with a taste in my mouth that worsens almost daily as I read of corporate and governmental greed. No longer do I find heroes and good deeds. I find that stockholder (voter) loyalty justifies all actions. What is good for our country, state, society, mankind and/or public health are but quaint and noble concepts useful only to guide thinking once stockholder profits are satisfied.

A simple reductase inhibitor

Look at Pfizer’s opening paragraph of Lipitor’s description.

“Lipitor is a reductase inhibitor. This enzyme catalzyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in cholesterol metabolism. Mevalonate is a precurser of sterols, including cholesterol.”

That is it, ladies and gentlemen. That is all they said about mevalonate. They basically admit the statin class of drugs is going to “seriously inhibit mevalonate” in a manner of speaking but never a word about what that really means for the human body! To reduce your cholesterol by 40% is to reduce your mevalonate by 40%. Are you interested in what this really means?

This opening statement is the very beginning of Pfizer’s current program of misrepresentation, deception, prevarication, mendacity and downright lying about their product. And the truly sad thing about all this is that, out of their personal ignorance of our “mevalonate pathway” and their unfortunate susceptibility to the Pied Piper tidings of well-trained drug “reps”, most of our clinicians believe this obfuscation from the drug company and are enthusiastically aiding and abetting Big Pharma in its sales drive.

Inhibiting Coenzyme Q 10

The drug companies knew from the very beginning that CoQ10 would be inhibited, just like cholesterol. Merck even filed a patent for a CoQ10/statin combined pill.

Canada advised CoQ10 co-administration with statins from the very beginning of marketing back in 1990. Were Canada’s governmental and corporate officials more informed than those of the United States? No, just more compassionate, while ours were being unduly influenced by the possible negative effect on marketing of a combined pill or of recommendations for CoQ10 supplementation.

This was the beginning of the sour taste in my mouth. CoQ10 depletion has been the cause of many thousands of side effects, especially the neuropathies, myopathies and rhabdomyolysis cases. Some of these cases have been fatal. Many have resulted in chronic disabilities.

Glycoprotein synthesis and dolichols

The next branch on the mevalonate pathway tree to suffer inevitable depletion from statins was the production of dolichols, vital to the synthesis of glycoproteins, and the attachment of sugars necessary for cell identification, cell messaging, neuropeptide synthesis and immunodefense. This is all on my website (see spacedoc.net).

Just pick up a copy of any medical school biochemistry text for a review of glycoprotein synthesis and dolichol’s prominent role. Although taught this as freshmen, most doctors have forgotten long ago the complex interplay of sugars and proteins, orchestrated by dolichols.

No, I have to admit, when I first heard of statin’s effect on our mevalonate pathway, I did not review the subject in my old chemistry book. I just accepted the words of the drug industry to do right. You have to have some faith, don’t you? It hurts when your faith fails you.

Phosphorylation and the tau protein

The next branch of the mevalonate tree to suffer from statin effect is our normal phosphorylation process resulting in both tau protein enhancement and inhibition of embryonic stem cell self-renewal. No I am not making this up. It comes right out of our current research literature. Sure it’s on mice. We’re guinea pigs aren’t we? That makes us close.

I do not wish to elaborate on the consequences of this but will remind you that just two months ago the World Health Organization reported excess ALS among statin users worldwide. Did you know that tau protein is the stuff of neurofibrillatory tangles and it’s not just in Alzheimers any more? And the mevalonate tree still has selenoprotein branches, Rho (the memory catalyst) and many others.

Drug companies to blame

Should I be the one to advise the pharmaceutical industry that they should not intentionally block our mevalonate pathway? In so doing they have created a nation of guinea pigs, an entire population devoted to seeing what would happen. And blocking our glial cell cholesterol production was more of the same thing. Despite Pfrieger’s publishing of the mechanism by which our statin drugs inhibit memory only five years ago, have we seen the slightest recognition of culpability by FDA or the drug industry? You got it – not a word!

I am appalled that organizations I once regarded as sharing a pedestal with God and motherhood, behave in such a callous manner. My deep respect has been forever shattered.

The guinea pig club

The statin guinea pig club is you, especially you who have been touched by the side effects of statins!

Day by day we are learning the true effects of statin drugs on our mevalonate pathways. Things the statin drug manufacturers should have known long before they requested FDA approval. But you must remember that back when these drugs were first coming to market, cholesterol was public health enemy number one and these cholesterol inhibitors were high priority.

Very few questions were asked by an agency concerned more with rapid approval than picky questions. Anything that would lower cholesterol was a friend of man, no questions asked. Obviously the research scientists knew they were in uncharted water and quite possibly they made their questions and anxieties known to management but in this cost plus effectiveness sparring that took place in the back rooms, research clearly lost to management pressure. Billions of dollars were at stake.

I am not going to tell you these research scientists did not know what was going to happen. Of course they knew the importance of the mevalonate pathway. Of course they knew that blocking this pathway at its very origin was bound to have serious complications. This was their job, their training and their life but they were over-ridden. Billions of dollars create a great deal of pressure, sweetened only by the presumption that if you lower cholesterol 1% you would add 2 years to life. How many times did I hear that in the days of the Framingham study.

The anti-cholesterol bandwagon needed the statins badly and whatever safeguards we had proved to be very flexible. One might say the almighty noise of the bandwagon drowned out the voices of caution and reason. Only in the past decade did the noise of the bandwagon diminish sufficiently to let truths begin to emerge.

The truth will out

The first thing that happened was that the consequences of CoQ10 inhibition gradually leaked out (see spacedoc.net). A major part of our mevalonate pathway is directed at CoQ10 synthesis. As a consequence, CoQ10 plummets after statins are started and we found patient after patient with muscle damage, rhabdomyolysis, neuropathy, congestive heart failure and serious fatigue all related one way or another to lack of CoQ10. Supplementation of CoQ10 started usually at the patient’s insistence, not the doctor’s.

The next important event was Frank Pfreiger’s astounding revelation in 2003 of the importance of cholesterol to brain function. Our brain’s synapses cannot function without sufficient cholesterol and since the LDL/cholesterol molecule is much too large to pass the blood/brain/barrier, nature had devised an alternative means of manufacture - the housekeeping cells of the brain, known as glial cells. Of course, these gli